Identification of compounds that selectively target highly chemotherapy refractory neuroblastoma cancer stem cells

Insights

Cuban propolis compounds show promise against therapy-resistant neuroblastoma cancer stem cells (CSCs). These natural molecules, particularly PPAPs, exhibit significant anti-CSC activity, offering potential new treatments for this challenging infant cancer.

Area of Science:

  • Natural Product Chemistry
  • Cancer Biology
  • Pharmacology

Background:

  • Cancer stem cells (CSCs) drive relapse due to resistance mechanisms like dormancy and multidrug resistance (MDR).
  • Neuroblastomas are aggressive infant tumors with poor survival rates and limited effective chemotherapy options.
  • Existing treatments struggle to specifically target and eliminate CSCs, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To investigate the potential of small molecules from Cuban propolis as anti-cancer agents against neuroblastoma cancer stem cells (CSCs).
  • To identify specific compounds with cytotoxic activity against therapy-refractory neuroblastoma-derived CSCs (iCSCs).
  • To explore the mechanisms of action of these propolis-derived compounds.

Main Methods:

  • Isolation and identification of compounds from Cuban propolis using RT-HPLC, mass spectrometry, and NMR.
  • Generation of induced CSCs (iCSCs) from LAN-1 neuroblastoma cells.
  • Cytotoxicity screening using MTT assays in sensitive cell lines and neuroblastoma iCSC models.

Main Results:

  • Several compounds, predominantly polycyclic polyprenylated acylphloroglucinols (PPAPs), demonstrated significant anti-iCSC activity.
  • Two compounds, including a flavonoid, were found to disrupt tubulin polymerization.
  • An unidentified compound strongly inhibited topoisomerases I/II and DNA polymerase.

Conclusions:

  • Small molecules isolated from Caribbean propolis exhibit promising cytotoxic activity against neuroblastoma CSCs.
  • These compounds, particularly PPAPs, represent potential therapeutic leads or drug candidates for treating chemotherapy-refractory neuroblastomas.
  • Further research into their specific molecular targets and mechanisms is warranted.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.3K